Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €16.88 EUR
Change Today +0.419 / 2.55%
Volume 61.0
BSX On Other Exchanges
New York
As of 1:55 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €17.45
52 Week Low
10/15/14 - €8.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

24,000 Employees
Last Reported Date: 02/25/15
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $921.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $450.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Executive Vice President and President of Rhy...
Total Annual Compensation: $454.1K
Senior Vice President and President of Interv...
Total Annual Compensation: $392.8K
Compensation as of Fiscal Year 2014.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Appoints Professor John Mark Morgan as Senior Medical Director, Rhythm Management, Effective from September 1, 2015

Boston Scientific Corporation announced the appointment of Professor John Mark Morgan as senior medical director, Rhythm Management, effective from September 1, 2015. Prof. Morgan, an internationally recognised expert clinician in the field of cardiac rhythm management, will help shape and influence the advancement of medical therapies across all areas of the Cardiac Rhythm Management division, with a particular focus on Europe. Prof. Morgan currently serves as consultant cardiologist, specialist in Cardiac Rhythm Management at University Hospital Southampton NHS Trust, and honorary professor of Cardiac Rhythm Management at the University of Southampton, United Kingdom. He will leave his NHS appointment from September 1st but will continue his academic affiliations. He has supervised many postdoctoral students, has a research portfolio of more than 300 publications and has made contributions to the understanding of cardiac defibrillation, sudden cardiac death risk stratification and ICD therapy, cardiac resynchronization therapy, use of implantable technologies for the management of heart failure, and treatment of complex arrhythmias, with some particular interest in adult congenital heart disease.

Boston Scientific Reports Positive, Long-Term Data from the Evolve Trial of the Synergy Bioabsorbable Polymer Platinum Chromium Coronary Stent System

Boston Scientific reported positive, long-term data from the EVOLVE Trial of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no new major adverse cardiac events reported between years three and four.  The study results were presented for the first time at EuroPCR 2015 by Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. Findings from year four of the EVOLVE Trial include the following key performance measures: the target lesion revascularization (TLR) rate was 1.1% compared to 6.1% for the PROMUS Element™ Plus Stent System (p=0.07); and no definite or probable stent thrombosis (ST) was observed. The EVOLVE Trial is the first human use, prospective, randomized, single-blind study evaluating the non-inferiority of the SYNERGY Stent, which employs an ultrathin bioabsorbable polymer coating applied to the abluminal (outer) surface of the stent.  The comparator, the Boston Scientific PROMUS Element Plus Stent System, utilizes a durable polymer coating applied to the entire stent (inner and outer) surface.  EVOLVE is the first in a continuing cadence of clinical trials evaluating the performance of the SYNERGY Stent in a range of patients. In addition to these long-term data from the EVOLVE Trial, one-year findings from the EVOLVE II pivotal trial of 466 patients with diabetes treated with the SYNERGY Stent were presented by Stephan Windecker M.D., chief of cardiology and head of invasive cardiology at the Swiss Cardiovascular Center in Bern, Switzerland.  Patients with diabetes face an increased risk of heart disease, stroke and myocardial infarction.[1]  The data presented for patients with diabetes include the following: the TLR rate was 4.4%; and definite/probable ST was 1.1% at one year, with no definite/probable ST events after the first week post percutaneous coronary intervention (PCI). The EVOLVE II Trial includes a global, multi-center, randomized, single-blind, non-inferiority pivotal trial designed to evaluate the safety and performance of the SYNERGY Stent System compared to the durable polymer PROMUS Element Plus Stent System.  The trial enrolled 1,684 patients in 125 sites worldwide.  The EVOLVE II Trial is part of a rigorous clinical program designed to support the submission for U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the SYNERGY Stent. The EVOLVE II Trial also includes a non-randomized, single-arm diabetes study.  The EVOLVE II Diabetes Substudy pooled patients with diabetes randomized to the SYNERGY arm in the EVOLVE II pivotal trial with patients enrolled in the non-randomized single-arm diabetes study as pre-specified in the study protocol. Patients in the EVOLVE II Trial demonstrated clinical and angiographic complexity to a degree not observed in prior U.S. pivotal trials for drug-eluting stents (DES).  More than 25% of patients had non-ST elevation myocardial infarction (NSTEMI) and approximately 75 % of patients had AHA/ACC class B2/coronary lesions.  As previously reported, EVOLVE II met its primary endpoint, demonstrating non-inferiority of SYNERGY versus the PROMUS Element Plus Stent for 12-month target lesion failure in the overall patient population.

Boston Scientific Prices USD 1.85 Billion Three Series of Senior Notes

Boston Scientific announced that it had priced three series of senior notes for an aggregate principal amount of USD 1.85 billion. Of these notes, USD 600 million will mature on May 15, 2020 and will bear a coupon of 2.850%, USD 500 million of 3.375% notes are maturing on May 15, 2022, and USD 750 million of 3.850% notes are due May 15, 2025. The company plans to use the net proceeds from the offering to finance the takeover of American Medical Systems' urology portfolio, and to repay debt. The portfolio acquisition is expected to close in the third quarter of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:GR €16.88 EUR +0.419

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,812 JPY -8.00
Becton Dickinson and Co $140.51 USD -0.92
Olympus Corp ¥4,245 JPY +25.00
St Jude Medical Inc $73.75 USD -0.40
Zimmer Holdings Inc $114.09 USD +0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 3.8x
Price/Cash Flow 129.6x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at